Published in Transfusion on August 01, 1997
Safety of the blood supply in Latin America. Clin Microbiol Rev (2005) 1.78
Recommendations on hepatitis C screening for adults. CMAJ (2017) 1.07
Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review. BMC Public Health (2014) 0.84
In the clinic. Hepatitis C. Ann Intern Med (2008) 0.84
Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. BMC Infect Dis (2014) 0.80
Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell (1984) 5.56
Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet (1990) 4.99
Sexual transmission of hepatitis C virus. Lancet (1993) 4.27
Hepatitis C virus six years on. Lancet (1994) 4.09
Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet (1991) 3.97
Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J (1984) 3.28
Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet (1993) 3.20
White blood cell fragments in platelet concentrates prepared by the platelet-rich plasma or buffy-coat methods. Vox Sang (2005) 2.77
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang (2005) 2.47
Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J (1985) 2.47
Prevention of Yersinia enterocolitica growth in red-blood-cell concentrates. Lancet (1992) 2.44
Human parechovirus infections in Dutch children and the association between serotype and disease severity. Clin Infect Dis (2005) 2.41
Early detection of antibodies to HIV-1 by third-generation assays. Lancet (1992) 2.18
The primary structure of the putative oncogene pim-1 shows extensive homology with protein kinases. Cell (1986) 2.06
Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med (1996) 2.05
Evaluation of six enzyme immunoassays for antibody against human immunodeficiency virus. Lancet (1986) 2.04
Prevention of chronic HBsAg carrier state in infants of HBsAg-positive mothers by hepatitis B immunoglobulin. Lancet (1979) 2.03
Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol (1994) 2.02
Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J (Clin Res Ed) (1983) 1.86
Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol (1991) 1.83
Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. Lancet (1989) 1.82
Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis (2005) 1.80
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang (2011) 1.69
The duration of fixation influences the yield of HCV cDNA-PCR products from formalin-fixed, paraffin-embedded liver tissue. J Virol Methods (1994) 1.62
Cloned human snRNP proteins B and B' differ only in their carboxy-terminal part. EMBO J (1989) 1.59
Maternal genomic neutrophil FcRIII deficiency leading to neonatal isoimmune neutropenia. Blood (1990) 1.59
Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis (2006) 1.56
Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill (2013) 1.51
Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus. J Clin Microbiol (1992) 1.49
Hepatitis E in The Netherlands: imported and endemic. Lancet (1993) 1.45
Remuneration of blood donors: new proof of the pudding? Vox Sang (2008) 1.44
Efficacy of the latest generation of antibody assays for (early) detection of HIV 1 and HIV 2 infection. Vox Sang (1989) 1.43
Cord blood banking. Vox Sang (2008) 1.41
International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods (1996) 1.41
[Hepatitis C; a new virus for an old disease]. Ned Tijdschr Geneeskd (1992) 1.40
New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion (1998) 1.39
[The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis]. Ned Tijdschr Geneeskd (2005) 1.39
Universal leucocyte-depletion of blood components: cell concentrates and plasma. Vox Sang (2001) 1.39
New anti-human immunodeficiency virus immunoblot assays resolve nonspecific western blot results. Transfusion (1997) 1.38
Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol (1999) 1.37
Construction and characterization of deletion mutants of pseudorabies virus: a new generation of 'live' vaccines. J Gen Virol (1987) 1.36
Upstream regions of the hamster desmin and vimentin genes regulate expression during in vitro myogenesis. EMBO J (1987) 1.36
Donors with a rare pheno (geno) type. Vox Sang (2008) 1.35
Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J (1989) 1.35
Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol (1992) 1.33
Tumor progression in murine leukemia virus-induced T-cell lymphomas: monitoring clonal selections with viral and cellular probes. J Virol (1986) 1.24
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat (2015) 1.22
Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang (2003) 1.22
Blood donations reactive for HIV in Western blot, but non-infective in culture and recipients of blood. Lancet (1986) 1.18
Bacterial contamination in platelet concentrates. Vox Sang (2014) 1.18
Evaluation of a new haemagglutination technique for the demonstration of hepatitis-B antigen. Lancet (1973) 1.18
Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet (1983) 1.17
Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox Sang (2011) 1.16
Prevalence of anti-HCV antibodies confirmed by recombinant immunoblot in different population subsets in The Netherlands. Vox Sang (1991) 1.15
Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion (1995) 1.15
The primary structure of leucine aminopeptidase from bovine eye lens. J Biol Chem (1982) 1.14
Amplified-fragment length polymorphism analysis of Propionibacterium isolates implicated in contamination of blood products. Br J Haematol (2005) 1.13
High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. Vox Sang (1998) 1.09
Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients. Transfusion (1993) 1.09